

Lexaria Bioscience Corp.

11:30 23 Sep 2020

Lexaria Bioscience wins order commitments for 4.4M CBD servings of its patented DehydraTECH-enabled CBD powders

Lexaria Bioscience Corp (OTCQX:LXRP)(CNSX:LXX), a global innovator in drug delivery platforms, announced Wednesday it has purchase-order commitments for about 4.4 million CBD servings of its patented DehydraTECH-enabled CBD powders.

In a statement, the company added that the CBD servings were processed during its fiscal first quarter of 2021, which ends November 30, 2020.

Lexaria also said it has received verbal requests from existing licensees to prepare its facilities to produce at least 56 million servings during the calendar year 2021.

READ: Lexaria Bioscience wins ninth US patent as it expands patent portfolio

So far, about 1.2 million CBD servings already have been processed in fiscal 4Q ended August 31, 2020, along with some 700,000 CBD servings during the company's fiscal Q3 ended May 31, 2020. A serving generally ranges from 10 milligrams (mg) to 20mg of CBD each, utilizing the company's DehydraTECH patented processes.

"After a significant investment of time and operations optimization, Lexaria's DehydraTECH CBD business is gaining traction in the US market," said CEO Chris Bunka. "The benefits offered to DehydraTECH corporate clients, and the performance advantages enjoyed by end-users are inescapable."

Lexaria's business operations include both technology licensing wherein corporate licensees implement DehydraTECH under license within their own facilities under royalty agreements, and also corporate clients that purchase pre-processed DehydraTECH CBD-powders manufactured at a Lexaria-contracted GMP-certified food facility for shipment back to the client for integration into final product formats.

Fees payable to Lexaria contain a mixture of both manufacturing charges as well as royalty and trademark fees, the company noted.

The Kelowna, British Columbia-based Lexaria has developed and markets DehydraTECH, which masks unwanted tastes, improves onset speed and increases the bioavailability of active pharmaceutical ingredients in a simple and cost-effective platform.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Price: 0.26

Market Cap: \$23.41 m

1 Year Share Price Graph



Share Information

Code: LXX

Listing: CSE

52 week	High	Low
	0.75	0.22

Sector: Cannabis

Website: www.lexariabioscience.com

Company Synopsis:

Lexaria Bioscience Corp has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules. Many vitamins, drugs, supplements and other beneficial molecules are lipophilic (i. e.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).